© 2004 European Society of Cardiology
Clinical trials update from the American Heart Association meeting: 
-3 fatty acids and arrhythmia risk in patients with an implantable defibrillator, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, ORBIT and PAD and DEFINITE
a Department of Cardiology University of Hull, Castle Hill Hospital, Cottingham, Kingston-upon-Hull, HU15 5JQ, UK
b Department of Primary Care and General Practice University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
* Corresponding author. Tel.: +44-1482-624086; fax: +44-1482-624085. E-mail address: a.p.coletta{at}hull.ac.uk
 |
Abstract |
|---|
The American Heart Association meeting reported the results of several clinical trials of particular interest to those who care for patients with heart failure. 
-3 fatty acids were associated with a trend to increased recurrence of ventricular arrhythmias but not mortality in patients with an implantable debrillator. The ACTIV in CHF study provides more evidence of a therapeutic role for arginine vasopressin antagonists in the treatment of heart failure. The VALIANT study provides further evidence to suggest that a combination of angiotensin receptor antagonist and ACE inhibitor does not reduce mortality but may reduce morbidity in post-MI patients with heart failure or major LV systolic dysfunction. A study of autologous bone marrow cell transplantation into myocardial scar give gave encouraging results. SPORTIF V showed ximelagation to be as effective as warfarin but with improved safety. ORBIT and PAD showed public access defibrillators saved lives but questioned their cost effectiveness. DEFINITE supported a role for ICDs in patients with non-ischemic cardiomyopathy, although cost-effectiveness remains in doubt.
Key Words: -3 fatty acids • ACTIV in CHF • VALIANT • The Hanover Autologous Bone Marrow Transplantation Study • SPORTIF V • ORBIT • PAD • DEFINITE
Received November 30, 2003; Accepted December 5, 2003
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Chrysohoou, D. B Panagiotakos, C. Pitsavos, J. Skoumas, X. Krinos, Y. Chloptsios, V. Nikolaou, and C. Stefanadis Long-term fish consumption is associated with protection against arrhythmia in healthy persons in a Mediterranean region--the ATTICA study Am. J. Clinical Nutrition, May 1, 2007; 85(5): 1385 - 1391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G.F. Cleland, A. P. Coletta, A. T. Abdellah, M. Nasir, N. Hobson, N. Freemantle, and A. L. Clark Clinical trials update from the American Heart Association 2006: OAT, SALT 1 and 2, MAGIC, ABCD, PABA-CHF, IMPROVE-CHF, and percutaneous mitral annuloplasty Eur J Heart Fail, January 1, 2007; 9(1): 92 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G.F. Cleland, N. Freemantle, A. P. Coletta, and A. L. Clark Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE Eur J Heart Fail, January 1, 2006; 8(1): 105 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G.F. Cleland, A. P. Coletta, M. Lammiman, K. K. Witte, H. Loh, M. Nasir, and A. L. Clark Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE Eur J Heart Fail, October 1, 2005; 7(6): 1070 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Kirkorian, H. Burri, J. G.F. Cleland, J.-C. Daubert, L. Tavazzi, and the CARE-HF Study Investigators Cardiac-Resynchronization Therapy in Heart Failure N. Engl. J. Med., July 14, 2005; 353(2): 205 - 206. [Full Text] [PDF]
|
|
|
|
|
|
A. Geelen, I. A Brouwer, E. G Schouten, A. C Maan, M. B Katan, and P. L Zock Effects of n-3 fatty acids from fish on premature ventricular complexes and heart rate in humans Am. J. Clinical Nutrition, February 1, 2005; 81(2): 416 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G.F. Cleland, J. Ghosh, N. Freemantle, G. C. Kaye, M. Nasir, A. L. Clark, and A. P. Coletta Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure Eur J Heart Fail, June 1, 2004; 6(4): 501 - 508. [Abstract] [Full Text] [PDF]
|
|